The American Journal of Surgery
Volume 199, Issue 1 , Pages 43-51 , January 2010

Heparin-induced thrombocytopenia in surgical patients

  • Sandra Battistelli, M.D.

      Affiliations

    • Department of Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci, 53100 Siena, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-0577-585164; fax: +39-0577-586126
    • ,
  • Alberto Genovese, M.D.

      Affiliations

    • Department of Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci, 53100 Siena, Italy
    • ,
  • Tommaso Gori, M.D.

      Affiliations

    • Department of Cardiology, University Hospital of Mainz, Germany

Received 6 November 2008 ,Revised 16 January 2009

References 

  1. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121:535–555
  2. Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res. 2006;118:165–176
  3. Warkentin TE. Heparin-induced thrombocytopenia. Disorders. 2005;51:141–149
  4. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost. 2004;30:273–283
  5. Arepally GM, Ortel TL. Clinical practice (Heparin-induced thrombocytopenia). N Engl J Med. 2006;355:809–817
  6. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 2005;105:131–138
  7. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis (A retrospective analysis of 408 patients). Thromb Haemost. 2005;94:132–135
  8. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In:  Warkentin TE,  Greinacher A editor. Heparin-Induced Thrombocytopenia. 4th edn.. New York: Informa Healthcare, USA, Inc; 2007;p. 67–116
  9. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286–1292
  10. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135:502–506
  11. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005 Oct. 15;106:2710–2715
  12. Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108:2937–2941
  13. McNulty I, Katz E, Kim KY. Thrombocytopenia following heparin flush. Prog Cardiovasc Nurs. 2005;20:143–147
  14. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163:2518–2524
  15. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703–1708
  16. Klenner AF, Lubenow N, Raschke R, et al. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost. 2004;91:719–724
  17. Matsuo T, Tomaru T, Kario K, et al. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. Thromb Res. 2005;115:475–481
  18. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:340–380
  19. Guyatt GH, Cook DJ, Jaeschke R, et al. Grades of recommendation for antithrombotic agents. Chest. 2008;133:123S–131S
  20. Chilver-Stainer L, Lämmle B, Alberio L. Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost. 2004;91:276–282
  21. Bennett-Guerrero E, Slaughter TF, White WD, et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg. 2005;130:1567–1572
  22. Calaitges JG, Liem TK, Spadone D, et al. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg. 1999;29:779–785
  23. Greinacher A, Eichler P, Lietz T, et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood. 2005;106:2921–2922
  24. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med. 2004 Febr. 23;164:361–369
  25. Hong AP, Cook DJ, Sigouin CS, et al. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 2003;101:3049–3051
  26. Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest. 2006;129:1407–1416
  27. Fabris F, Luzzatto G, Soini B, et al. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med. 2002;252:149–154
  28. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol. 2004;76:240–244
  29. Warkentin TE, Kelton JGA. 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502–507
  30. Workentin TE. Clinical picture of heparin-induced thrombocytopenia. In:  Warkentin TE,  Greinacher A editor. Heparin-Induced Thrombocytopenia. 4th edn.. New York: Informa Healthcare, USA, Inc; 2007;p. 21–66
  31. Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996;92:494–497
  32. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest. 2005;127(suppl):35S–45S
  33. Lewis BE, Wallis DE, Berkowitz SD, et al. ARG-911 Study Investigators Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838–1843
  34. Lubenow N, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-induced thrombocytopenia—results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005;3:2428–2436
  35. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759–765
  36. Walenga JM, Jeske WP, Fasanella AR, et al. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost. 1999;25(suppl 1):43–49
  37. Walenga JM, Jeske WP, Fasanella AR, et al. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb/Hemost. 1999;5(suppl 1):S21–S27
  38. Warkentin TE, Sheppard JA. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev. 2006;20:259–272
  39. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia (Heparin-associated thrombocytopenia study (HAT) investigators). Circulation. 1999;100:587–593
  40. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73–80
  41. Tardy B, Lecompte T, Boelhen F, et al. GEHT-HIT Study Group Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006;108:1492–1496
  42. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation. 2003;108:2062–2065
  43. Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on APTT, and clinical relevance. Blood. 2000;96:2373–2378
  44. Lewis BE, Wallis DE, Leya F, et al. Argatroban-915 Investigators Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849–1856
  45. Mahaffey KW, Lewis BE, Wildermann NM, et al. ATBAT Investigators The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15:611–616
  46. Stone GW, McLaurin BT, Cox DA, et al. ACUITY Investigators Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203–2216
  47. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT) (A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004). Thromb Haemost. 2006;95:967–981
  48. Chong BH, Gallus AS, Cade JF, et al. Australian HIT Study Group Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001;86:1170–1175
  49. Farner B, Eichler P, Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001;85:950–957
  50. Walenga JM, Jeske WP, Bara L, et al. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res. 1997;86:1–36
  51. Petitou M, Duchaussoy P, Jaurand G, et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide. (SR 90,107A/orig 31,540) J Med Chem. 1997;40:1600–1607
  52. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106:3791–3796
  53. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 1997;8:114–117
  54. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb/Hemost. 1999;5:259–266
  55. Harenberg J, Jörg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica. 2004;89:1017–1018
  56. Bradner J, Hallisey RK, Kuter DJ. Fondaparinux in the treatment of heparin-induced thrombocytopenia. (abstract) Blood. 2004;104:1775
  57. Lobo B, Finch C, Howard A, et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost. 2008;99:208–214
  58. Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost. 2005;93:999–1000
  59. Stratmann G, deSilva AM, Tseng EE, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004 Jun;98:1635–1639
  60. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106:2550–2554
  61. Yee AJ, Kuter DJ. Successful recovery from an overdose of argatroban. Ann Pharmacother. 2006;40:446–449
  62. Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med. 2004;164:1961–1964

PII: S0002-9610(09)00261-X

doi: 10.1016/j.amjsurg.2009.01.029

The American Journal of Surgery
Volume 199, Issue 1 , Pages 43-51 , January 2010

Article Tools

* Image Usage & Resolution